Reaching Patients Throughout the World

BioMarin is a multinational commercial biopharmaceutical company providing important therapeutic treatments to hundreds of patients around the world who might otherwise go untreated.

Our global sales force continues to solidify the company's commercial presence in the United States and Europe and is rapidly expanding into other regions such as Latin America and the Middle East where the incidence of MPS VI is more widespread. Sales representatives work closely with genetic centers to educate pediatricians and general practitioners about the signs and symptoms of MPS VI and other lysosomal storage disorders. By raising awareness about these rare diseases, we hope that individuals with MPS and other lysosomal storage disorders will be referred more promptly to genetic centers for testing, diagnosis and treatment.

The company's newest product, Kuvan for PKU, was approved in just a little over three years after the IND filing and was successfully launched within days of its approval by the FDA. Similarly, both Naglazyme and Aldurazyme were successfully developed and commercialized in about five years--a rate far surpassing that of industry standards.

Looking ahead, as other products advance through the clinic and near marketing approval, we will evaluate the need to scale-up our sales force in order to ensure additional successful product launches.

To discuss potential partnership opportunities, please contact our Business Development group at bd@bmrn.com.